Proof of concept: Network and systems biology approaches aid in the discovery of potent anticancer drug combinations

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3137-3144

  Azmi, Asfar S ^a   Wang, Zhiwei ^a   Philip, Philip A ^a   Mohammad, Ramzi M ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MI 219; OXALIPLATIN; UNCLASSIFIED DRUG;

DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 78650345652     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0642     Document Type: Review

References (39)

1. Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 2009;9: 307-19.
2. Newell DR. How to develop a successful cancer drug-molecules to medicines or targets to treatments? Eur J Cancer 2005;41:676-82.
3. Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: A genome-centric perspective. J Cell Physiol 2009;220:538-47.
4. Le Tourneau C, Stathis A, Vidal L, Moore MJ, Siu LL. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol 2010;28:1401-7.
5. Wist AD, Berger SI, Iyengar R. Systems pharmacology and genome medicine: A future perspective. Genome Med 2009;1:11.
6. Lander ES. Genomics: Launching a revolution in medicine. J Law Med Ethics 2000;28:3-14.
7. Stelzl U, Worm U, Lalowski M, et al. A human protein-protein interaction network: A resource for annotating the proteome. Cell 2005;122:957-68.
8. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: Archive for highthroughput functional genomic data. Nucleic Acids Res 2009;37: D885-90.
9. Drews J. Pharmaceuticals: Classes, therapeutic agents, areas of application volume 4. Drug Discov Today 2001;6:1100.
10. Drews J. Drug discovery: A historical perspective. Science 2000;287:1960-4.
11. Glaser B. Genetic analysis of complex disease-a roadmap to understanding or a colossal waste of money. Pediatr Endocrinol Rev 2010;7:258-65.
12. Moore PS, Sipos B, Orlandini S, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001;439:798-802.
13. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
14. Radulovich N, Qian JY, Tsao MS. Human pancreatic duct epithelial cell model for KRAS transformation. Methods Enzymol 2008;439: 1-13.
15. Kramer R, Cohen D. Functional genomics to new drug targets. Nat Rev Drug Discov 2004;3:965-72.
16. Russell RB, Aloy P. Targeting and tinkering with interaction networks. Nat Chem Biol 2008;4:666-73.
17. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
18. Pujol A, Mosca R, Farres J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010;31:115-23.
19. Faratian D, Clyde RG, Crawford JW, Harrison DJ. Systems pathology- taking molecular pathology into a new dimension. Nat Rev Clin Oncol 2009;6:455-64.
20. Stein A, Pache RA, Bernado P, Pons M, Aloy P. Dynamic interactions of proteins in complex networks: A more structured view. FEBS J 2009;276:5390-405.
21. Pache RA, Zanzoni A, Naval J, Mas JM, Aloy P. Towards a molecular characterisation of pathological pathways. FEBS Lett 2008;582:1259-65.
22. Kitano H. Cancer robustness: Tumour tactics. Nature 2003;426:125.
23. Pujana MA, Han JD, Starita LM, et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007;39:1338-49.
24. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009;25:2466-72.
25. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: Interaction and network perspectives. Nat Rev Drug Discov 2009;8:111-28.
26. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-70.
27. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009;49:223-41.
28. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 2008;105:3933-8.
29. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer 2009;9:862-73.
30. Azmi AS, Aboukameel A, Banerjee S, et al. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 2010;46:1122-31.
31. Azmi AS, Philip PA, Beck FW, et al. 219-zinc combination: A new paradigm in MDM2 inhibitor-based therapy. Oncogene 2010.Epub 2010 Sep 6.
32. Livengood JA, Scoggin KE, Van OK, et al. p53 Transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. J Biol Chem 2002;277:9054-61.
33. Abida WM, Gu W. p53-Dependent and p53-independent activation of autophagy by ARF. Cancer Res 2008;68:352-7.
34. Liu J, Grogan L, Nau MM, Allegra CJ, Chu E, Wright JJ. Physical interaction between p53 and primary response gene Egr-1. Int J Oncol 2001;18:863-70.
35. Chartier FL, Bossu JP, Laudet V, Fruchart JC, Laine B. Cloning and sequencing of cDNAs encoding the human hepatocyte nuclear factor 4 indicate the presence of two isoforms in human liver. Gene 1994;147:269-72.
36. Perilhou A, Tourrel-Cuzin C, Zhang P, et al. The MODY1 gene for hepatocyte nuclear factor 4alpha and a feedback loop control COUP-TFII expression in pancreatic beta cells. Mol Cell Biol 2008; 28:4588-97.
37. Yoshida E, Aratani S, Itou H, et al. Functional association between CBP and HNF4 in trans-activation. Biochem Biophys Res Commun 1997;241:664-9.
38. Rual JF, Venkatesan K, Hao T, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005;437: 1173-8.
39. Stelzl U, Wanker EE. The value of high quality protein-protein interaction networks for systems biology. Curr Opin Chem Biol 2006;10:551-8.